Kingdon Capital
Kingdon Capital Management, L.L.C. is an employee owned hedge fund sponsor. The firm provides its services to high net worth individuals
Business Model:
Revenue: $10M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Kingdon Capital Information
Geographic Data
Address: 57th street
City: New York
State: other
Zip: 10019
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Kingdon Capital Management, L.L.C. is an employee owned hedge fund sponsor. The firm provides its services to high net worth individuals and institutional clients. It invests in the public equity, fixed income, and alternative investment markets across the globe. The firm invests in growth and value stocks of all-cap companies. It also invests in currency futures and options and long/short strategies to hedge its client&s;s risks. It employs a top-down approach to select the economies and fundamental and technical analysis with a bottom-up stock picking approach to make investments. The firm conducts in-house research to make its investments. Kingdon Capital Management was founded in 1983 and is based in New York City.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2020 | Imago BioSciences | Series C | 80M |
| 6/2001 | Luminous Networks | Series D | 0 |
| 5/2022 | Sapience Therapeutics | Series B | 0 |
| 12/2004 | Mformation Technologies | Series D | 9M |
| 10/1999 | MessageMedia | Venture Round | 42M |
| 5/2007 | Mformation Technologies | Series E | 0 |
| 6/2000 | SandCraft | Series B | 0 |
| 11/2021 | Shoreline Biosciences | Series B | 0 |
| 8/2002 | SafeWeb | Series C | 0 |
| 6/2018 | Stealth BioTherapeutics | Convertible Note | 0 |
| 4/2017 | SteadyMed Therapeutics | Post-IPO Equity | 0 |
| 1/2017 | Napo Pharmaceuticals | Debt Financing | 0 |
| 12/2019 | Athenex | Post-IPO Equity | 60M |
| 3/2006 | Bill Me Later | Series A | 27.4M |
| 4/2021 | CeQur SA | Series C | 0 |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 5/2022 | Sapience Therapeutics | Series B | 0 |
| 11/2021 | Shoreline Biosciences | Series B | 0 |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 4/2021 | CeQur | Series C | 0 |
| 11/2020 | Imago BioSciences | Series C | 0 |
| 12/2019 | Athenex | Post-IPO Equity | 0 |
| 6/2018 | Stealth BioTherapeutics | Convertible Note | 0 |
| 4/2017 | SteadyMed Therapeutics | Post-IPO Equity | 0 |
| 1/2017 | Napo Pharmaceuticals | Debt Financing | 0 |
| 5/2007 | Mformation Technologies | Series E | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
